Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30570716 | 1.00 | DNMT1 (0.53) | DNMT1PTPRCALDH1A1MAPTRAB9A | |
| SCHEMBL3333300 | 0.87 | DNMT1 (0.62) | DNMT1PTPRCALDH1A1MAPTRAB9A | |
| SCHEMBL27927489 | 0.86 | DNMT1 (0.60) | DNMT1PTPRCALDH1A1MAPTRAB9A | |
| SCHEMBL9900718 | 0.80 | DNMT1 (0.70) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12236188 | 0.78 | DNMT1 (0.67) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30362207 | 0.78 | DNMT1 (0.67) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7122517 | 0.78 | DNMT1 (0.73) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL183078 | 0.77 | DNMT1 (0.78) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29612224 | 0.77 | DNMT1 (0.78) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29358121 | 0.77 | DNMT1 (0.78) | DNMT1ALDH1A1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4296365-B1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | VISOLIS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4296365-A2 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3224368-B1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | VISOLIS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11492339-B2 | Processes for conversion of biologically derived mevalonic acid | Visolis, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210078966-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-10807963-B2 | Processes for conversion of biologically derived mevalonic acid | Visolis, Inc. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190169153-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-10208008-B2 | Processes for conversion of biologically derived mevalonic acid | Visolis, Inc. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3224368-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016085987-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160145227-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492339-B2 | Processes for conversion of biologically derived mevalonic acid | COASY, FDPS, ME1 | DNMT1 2058/4885PTPRC 3980/4885ALDH1A1 1439/4885 |
| US-20160145227-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | COASY, FDPS, GGPS1 | DNMT1 2104/4885PTPRC 3666/4885ALDH1A1 1218/4885 |
| US-20190169153-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | COASY, FDPS, GGPS1 | DNMT1 2104/4885PTPRC 3666/4885ALDH1A1 1218/4885 |
| US-10208008-B2 | Processes for conversion of biologically derived mevalonic acid | COASY, FDPS, ME1 | DNMT1 2058/4885PTPRC 3980/4885ALDH1A1 1439/4885 |
| US-10807963-B2 | Processes for conversion of biologically derived mevalonic acid | COASY, FDPS, ME1 | DNMT1 2058/4885PTPRC 3980/4885ALDH1A1 1439/4885 |
| US-20210078966-A1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | COASY, FDPS, ME1 | DNMT1 2058/4885PTPRC 3980/4885ALDH1A1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.